The Blueprint: Genetics and Diagnostic Testing

While many patients with immune issues are given a broad diagnosis of Common Variable Immunodeficiency (CVID), genetic testing allows doctors to look “under the hood” at the specific blueprints of your immune system. For you, the focus is on the IKZF1 gene, which provides the instructions for the IKAROS protein ^[1].

Getting to this diagnosis often involves looking at how your genetic variants behave and tracking your immune cells over several years.

Three Ways a Gene Can “Misbehave”

Not all IKZF1 mutations are the same. Depending on where the pathogenic variant occurs in your genetic code, the IKAROS protein can fail in three distinct ways. Note that this is a simplified framework; variant mechanism can be difficult to establish, genotype-phenotype overlap exists, and the variant’s location or label alone does not perfectly determine prognosis. Classification requires expert laboratory/genetic interpretation.

• Haploinsufficiency (HI): This is the “not enough” category. One copy of your gene is missing or broken, leaving you with only half the normal amount of functional IKAROS protein ^[2]. This typically causes the CVID-like phenotype—meaning you mainly struggle with low antibodies and frequent sinus or lung infections ^[3].
• Dominant-Negative (DN): This is the “spoiler” category. The mutated protein not only fails to work but actually interferes with the healthy protein produced by your other gene copy ^[4]. This is usually more severe and causes Combined Immunodeficiency (CID), affecting both B-cells and T-cells, and often leads to a high risk of unusual infections like Pneumocystis pneumonia early in life ^[5][6].
• Gain-of-Function (GoF): This is the “overactive” category. The protein becomes hyperactive or works in ways it shouldn’t, often leading to immune dysregulation—where the body is prone to allergies, asthma, and severe inflammation rather than just infections ^[7][5].

Screening Newborns: TRECs vs. KRECs

In many regions, babies are screened at birth for severe immune issues using a heel-prick blood test. This test looks for two specific “circles” of DNA that are created when immune cells are born:

• TRECs (T-cell Receptor Excision Circles): These show if the body is making T-cells.
• KRECs (Kappa-recombining Excision Circles): These show if the body is making B-cells.

TREC screening is designed primarily to detect severe T-cell lymphopenia and is not a reliable screen for all IKZF1-related disease. Screening results vary by variant and program. While undetectable KRECs have been reported in severe cases, KREC screening is not included in all jurisdictions, low KRECs are not specific to IKZF1, and B-cell output may be normal early in some haploinsufficient patients. A normal newborn screen cannot predict later progressive antibody deficiency ^[6][4].

Why “One and Done” Testing Isn’t Enough

Diagnosis and monitoring of IKAROS disorders require longitudinal tracking—meaning tests are repeated over months and years. This is critical because the condition is often progressive ^[8].

A patient might have normal antibody levels (IgG, IgA, IgM) and “okay” B-cell counts at age five, but see those numbers steadily drop by age fifteen ^[8][9]. Your doctors use several tools to track this:

1. Quantitative Immunoglobulins: Measuring the total “amount” of antibodies in your blood.
2. Vaccine-Specific Antibodies: Checking if your body can actually use those antibodies to remember a “target,” such as the tetanus or pneumonia vaccine ^[9].
3. B-cell Subsets (Flow Cytometry): A detailed look at the B-cells to see if they are maturing properly or getting stuck in an “immature” phase ^[10].

Serial laboratory trends alone do not determine when immunoglobulin replacement should begin. Decisions should integrate infection history, quantitative immunoglobulins, vaccine responses, B-cell phenotype, age, and secondary causes. Also, vaccine-specific antibody testing can be uninterpretable after you start IVIG or SCIG because of passively transferred antibodies. Even if your levels look stable today, regular check-ups are the “early warning system” for your immune health.